Inhibition of BET proteins by novel inhibitor, PLX51107, regulates Fc-gamma receptor function and reduces inflammation in rheumatoid arthritis
Loading...
Date
2021-05
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
The Ohio State University
Abstract
Members of the Bromodomain Extra-Terminal Domain (BET) family — BRD2, BRD3,
BRD4, and BRDT — are key regulators of transcription. BET inhibition is associated with reduced
immune responses, making the BET family a potential therapeutic target for autoimmune diseases,
including rheumatoid arthritis (RA). Autoimmune disease pathogenesis is dependent on the
overactivation of immune responses. This includes the heightened production of inflammatory
cytokines, like TNFα, and secretion of autoantibodies, such as isotypes of rheumatoid factor and
anticitrullinated protein antibody (ACPA), which target healthy tissues. Fcγ receptors (FcγR)
expressed on the surface of myeloid cells bind Immunoglobulin G (IgG) immune complexes;
FcγRIa, FcγRIIa, FcγRIIIa are activating FcγR, whereas FcγRIIb is an inhibitory FcγR.
Recognition of autoantibodies by FcγRs induces an inflammatory phenotype that results in tissue
damage and further escalation of the inflammatory response.
Here we examine a novel BET inhibitor, PLX51107, and its effect on regulating FcγR
expression and function in RA. PLX51107 substantially upregulated FcγRIa and downregulated
FcγRIIa, FcγRIIb, FcγRIIIa, and FcϵR1-γ (γ-chain) — FcγRIa and FcγRIIIa's associated signaling
protein — mRNA and protein levels in healthy donor and RA monocytes. Consistent with this,
PLX51107 treatment decreased phagocytic and rosetting indexes, FcγR-mediated NF-κB, AKT,
and MAPK signaling, and TNFα production, indicating the attenuation of the immune response.
Our findings suggest that BET inhibition may have clinical relevance in the treatment of
RA. Further studies are critical to explore how BET inhibition mechanistically regulates FcγRs to
alleviate their mediated inflammatory responses, and to determine if BET inhibition, via
PLX51107, is therapeutic in a murine model of RA.
Description
Denman Undergraduate Research Forum: First Place in the Innovations in Medical Treatment Category
The Ohio State University College of Medicine Trainee Research Day Poster Award
The Ohio State University College of Medicine Trainee Research Day Poster Award
Keywords
Innate Immunity, Rheumatoid Arthritis, Monocytes and Macrophages, BET Inhibitors, Fc-gamma Receptors, Immunology